Lamivudine/raltegravir, sold under the brand name Dutrebis, is a combination medication of lamivudine and raltegravir which is used in the treatment of HIV/AIDS. It is taken by mouth. Side effects may include lactic acidosis, pancreatitis, liver failure, and severe skin rashes. It was approved for medical use in the United States in 2015.
- "Dutrebis (lamivudine and raltegravir)" (PDF). FDA. Retrieved 10 December 2017.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|